PMID- 32203213
OWN - NLM
STAT- MEDLINE
DCOM- 20201222
LR  - 20210317
IS  - 1532-1827 (Electronic)
IS  - 0007-0920 (Print)
IS  - 0007-0920 (Linking)
VI  - 122
IP  - 9
DP  - 2020 Apr
TI  - Differential prognostic impact of CD8(+) T cells based on human leucocyte antigen 
      I and PD-L1 expression in microsatellite-unstable gastric cancer.
PG  - 1399-1408
LID - 10.1038/s41416-020-0793-y [doi]
AB  - BACKGROUND: The aim of the study was to determine the human leucocyte antigen 
      class-I (HLA-I), programmed death-ligand 1 (PD-L1) expression and 
      tumour-infiltrating lymphocytes (TILs) of microsatellite instability-high gastric 
      cancer. METHODS: The HLA-I expression type was determined by immunohistochemistry 
      of HLA-A, HLA-B, HLA-C and beta2-microglobulin in the centre of the tumour (CT) and 
      in the invasive margin (IM) of samples from 293 patients (total loss vs. 
      preserved type). PD-L1 expression and TIL density was examined 
      immunohistochemically. HLA-I genotyping was also performed. RESULTS: The 
      expression loss of the HLA-I molecules was significantly associated with low TIL 
      density. According to survival analyses, the HLA-I expression type and PD-L1 
      positivity were not independent prognostic factors. The TIL density had no 
      prognostic implication when survival analysis was performed for the whole patient 
      group; however, high CD8(+) TIL infiltration was significantly associated with 
      good prognosis in only HLA-I-preserved-type/PD-L1-positive group (p = 0.034). The 
      homozygosity of the HLA-I allele was more frequently observed in the total loss 
      type group. CONCLUSIONS: We confirmed differential prognostic implication of 
      CD8(+) TILs according to the HLA-I and PD-L1 expression. Determination of the 
      HLA-I expression could be helpful to select patients who would benefit from 
      anti-PD-1/PD-L1 therapy.
FAU - Kwak, Yoonjin
AU  - Kwak Y
AD  - Department of Pathology, Seoul National University Hospital, Seoul National 
      University College of Medicine, Seoul, South Korea.
FAU - Koh, Jiwon
AU  - Koh J
AD  - Department of Pathology, Seoul National University Hospital, Seoul National 
      University College of Medicine, Seoul, South Korea.
FAU - Park, Yujun
AU  - Park Y
AD  - Department of Pathology, Seoul National University Bundang Hospital, Seoul 
      National University College of Medicine, Seongnam, South Korea.
FAU - Hong, Yun Ji
AU  - Hong YJ
AD  - Department of Laboratory Medicine, Seoul National University Bundang Hospital, 
      Seoul National University College of Medicine, Seongnam, South Korea.
FAU - Park, Kyoung Un
AU  - Park KU
AD  - Department of Laboratory Medicine, Seoul National University Bundang Hospital, 
      Seoul National University College of Medicine, Seongnam, South Korea.
FAU - Kim, Hyung-Ho
AU  - Kim HH
AD  - Department of Surgery, Seoul National University Bundang Hospital, Seoul National 
      University College of Medicine, Seongnam, South Korea.
FAU - Park, Do Joong
AU  - Park DJ
AD  - Department of Surgery, Seoul National University Bundang Hospital, Seoul National 
      University College of Medicine, Seongnam, South Korea.
FAU - Ahn, Sang-Hoon
AU  - Ahn SH
AD  - Department of Surgery, Seoul National University Bundang Hospital, Seoul National 
      University College of Medicine, Seongnam, South Korea.
FAU - Kim, Woo Ho
AU  - Kim WH
AD  - Department of Pathology, Seoul National University Hospital, Seoul National 
      University College of Medicine, Seoul, South Korea.
FAU - Lee, Hye Seung
AU  - Lee HS
AD  - Department of Pathology, Seoul National University Bundang Hospital, Seoul 
      National University College of Medicine, Seongnam, South Korea. hye2@snu.ac.kr.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200317
PL  - England
TA  - Br J Cancer
JT  - British journal of cancer
JID - 0370635
RN  - 0 (B7-H1 Antigen)
RN  - 0 (CD274 protein, human)
RN  - 0 (Histocompatibility Antigens Class I)
RN  - 0 (PDCD1 protein, human)
RN  - 0 (Programmed Cell Death 1 Receptor)
SB  - IM
MH  - B7-H1 Antigen/antagonists & inhibitors/*genetics/immunology
MH  - CD8-Positive T-Lymphocytes/immunology/pathology
MH  - Disease-Free Survival
MH  - Female
MH  - Genotype
MH  - Histocompatibility Antigens Class I/genetics/immunology
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - Lymphocytes, Tumor-Infiltrating/metabolism/pathology
MH  - Male
MH  - *Microsatellite Instability
MH  - Middle Aged
MH  - Programmed Cell Death 1 Receptor/antagonists & inhibitors/*genetics/immunology
MH  - Stomach Neoplasms/*genetics/immunology/pathology
MH  - Tumor Microenvironment/genetics/immunology
PMC - PMC7189244
COIS- The authors declare no competing interests.
EDAT- 2020/03/24 06:00
MHDA- 2020/12/23 06:00
PMCR- 2021/03/17
CRDT- 2020/03/24 06:00
PHST- 2019/07/22 00:00 [received]
PHST- 2020/02/25 00:00 [accepted]
PHST- 2020/01/29 00:00 [revised]
PHST- 2020/03/24 06:00 [pubmed]
PHST- 2020/12/23 06:00 [medline]
PHST- 2020/03/24 06:00 [entrez]
PHST- 2021/03/17 00:00 [pmc-release]
AID - 10.1038/s41416-020-0793-y [pii]
AID - 793 [pii]
AID - 10.1038/s41416-020-0793-y [doi]
PST - ppublish
SO  - Br J Cancer. 2020 Apr;122(9):1399-1408. doi: 10.1038/s41416-020-0793-y. Epub 2020 
      Mar 17.